A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Ruxolitinib dose management as a key to long-term treatment success.

Evaluating Elevated Hemoglobin-Reply.

Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.

Recent advances in the management of myelofibrosis.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.

Elevated Hemoglobin or Hematocrit Level.

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.